Table 1 (Abstract A15). Patient and clinical characteristics at baseline

Age at disease onset, years (median, IQR)

13.2 (9.5–14.8)

11.4 (5.7–13.3)

Disease duration at baseline, years (median, IQR)

1.4 (1.1–3.0)

1.1 (0.1–1.9)

Antinuclear antibody (ANA)-/ dsDNA-antibody- positive (%)

84.2%/84.2%

91.7/66.7

Reduced C3-/C4-complement levels (%)

42.1/31.6

58.3/25.0

Antiphospholipid-antibodies (%)

21.1

50

Lupus-nephritis, n(%)

1 (5.3)

2 (16.7)

Lupus-encephalitis n(%)

0

1 (8.3)

Hematologic manifestations n(%)

6 (31.6)

7 (58.3)

Skin manifestations (excluding butterfly-rash) n(%)

2 (10.6)

0

Physician global assessment disease activity (scale 0–100), (median, IQR)

31 (18–60)

37 (0–54)

Patient global assessment disease activity (scale 0–100), (median, IQR)

31.5 (0–53)

27 (10–44)

Ds-DNA antibodies (IU/ml)

167.5 (12–229)

24 (6–161)

Complement-C3 levels (mg/dl)

97 (76–105)

77 (63–99)

Complement-C4 levels (mg/dl)

13 (5.5–17)

11.5 (3.3–17)

Selena-SLEDAI score (points)

7 (4–8)

7 (2–14)

Steroids (%)

100

75

Hydroxychloroquine (%)

94,7

83,3

Azathioprine/ methotrexate/ mycophenolate mofetil (%)

10.5/15.8/47.4

8.3/0/58.3